Mylan Claims Ranbaxy Sitting On Hypertension Drug Exclusivity

By Erica Teichert (December 7, 2012, 7:30 PM EST) -- Mylan Pharmaceuticals Inc. told a Washington federal judge on Friday that it should be allowed to start marketing a generic version of its hypertension drug valsartan, alleging Ranbaxy Laboratories Ltd. has forfeited its exclusivity rights by not actively pursuing U.S. Food and Drug Administration approval....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!